当前位置: X-MOL 学术JAMA Ophthalmol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Association of Ocular Adverse Events With Inactivated COVID-19 Vaccination in Patients in Abu Dhabi
JAMA Ophthalmology ( IF 8.1 ) Pub Date : 2021-10-01 , DOI: 10.1001/jamaophthalmol.2021.3477
Francesco Pichi 1, 2 , Shaikha Aljneibi 1 , Piergiorgio Neri 1, 2 , Steven Hay 1 , Christine Dackiw 1 , Nicola G Ghazi 1
Affiliation  

Importance As vaccinations against COVID-19 continue, potential ocular adverse events should be reported in detail to increase awareness among the medical community, although typically, a causal relationship cannot be established definitively.

Objective To describe ocular adverse events that occur soon after receiving an inactivated COVID-19 vaccination (Sinopharm).

Design, Setting, and Participants This case series took place from September 2020 to January 2021 at Cleveland Clinic Abu Dhabi, a tertiary referral center. Patients who reported ocular adverse events and presented within 15 days from the first of 2 doses of an inactivated COVID-19 vaccine were analyzed.

Main Outcomes and Measures Each patient underwent Snellen best-corrected visual acuity that was then converted to logMAR, applanation tonometry, and biomicroscopic examination with indirect ophthalmoscopy. Color fundus photography was obtained with a conventional 9-field fundus photography camera or with a widefield fundus photography system. Optical coherence tomography and optical coherence tomographic angiography images were obtained. Sex, race, age, and clinical data were self-reported.

Results Nine eyes of 7 patients (3 male individuals) presenting with ocular complaints following COVID-19 vaccine were included in the study. The mean (SD) age was 41.4 (9.3) years (range, 30-55 years); the mean best-corrected visual acuity was 0.23 logMAR (range, 0-1 logMAR; approximate Snellen equivalent, 20/32). The mean time of ocular adverse event manifestations was 5.2 days (range, 1-10 days). One patient was diagnosed with episcleritis, 2 with anterior scleritis, 2 with acute macular neuroretinopathy, 1 with paracentral acute middle maculopathy, and 1 with subretinal fluid.

Conclusions and Relevance In this case series study of 7 patients, the timing of transient and ocular complications 5.2 days after vaccination with an inactivated COVID-19 vaccine supported an association with the ocular findings, but a causal relationship cannot be established from this study design.



中文翻译:

阿布扎比患者眼部不良事件与灭活 COVID-19 疫苗接种的关联

重要性 随着针对 COVID-19 的疫苗接种继续进行,应详细报告潜在的眼部不良事件,以提高医学界的认识,尽管通常无法确定因果关系。

目的 描述接种灭活 COVID-19 疫苗(国药集团)后不久发生的眼部不良事件。

设计、环境和参与者 本案例系列于 2020 年 9 月至 2021 年 1 月在三级转诊中心阿布扎比克利夫兰诊所进行。分析了报告眼部不良事件并在 2 剂灭活 COVID-19 疫苗中的第一剂后 15 天内出现的患者。

主要结果和措施 每位患者接受了 Snellen 最佳矫正视力,然后将其转换为 logMAR、压平眼压计和间接检眼镜的生物显微镜检查。彩色眼底摄影是使用传统的 9 视野眼底摄影相机或宽视野眼底摄影系统获得的。获得光学相干断层扫描和光学相干断层扫描血管造影图像。性别、种族、年龄和临床数据是自我报告的。

结果 本研究纳入了在接种 COVID-19 疫苗后出现眼部不适的 7 名患者(3 名男性)的 9 只眼睛。平均 (SD) 年龄为 41.4 (9.3) 岁(范围 30-55 岁);平均最佳矫正视力为 0.23 logMAR(范围,0-1 logMAR;近似 Snellen 等效值,20/32)。眼部不良事件表现的平均时间为 5.2 天(范围为 1-10 天)。确诊为巩膜外层炎1例,前巩膜炎2例,急性黄斑神经视网膜病变2例,旁中央急性中间黄斑病变1例,视网膜下液1例。

结论和相关性 在这项针对 7 名患者的病例系列研究中,接种灭活 COVID-19 疫苗后 5.2 天出现短暂和眼部并发症的时间支持与眼部发现的关联,但无法从本研究设计中建立因果关系。

更新日期:2021-10-21
down
wechat
bug